Shield Therapeutics (LSE:STX) Other Net Income (Loss) : £-0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Other Net Income (Loss)?

Shield Therapeutics's Other Net Income (Loss) for the six months ended in Dec. 2024 was £0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was £-0.00 Mil.

Shield Therapeutics's quarterly Other Net Income (Loss) declined from Dec. 2023 (£0.00 Mil) to Jun. 2024 (£-0.00 Mil) but then increased from Jun. 2024 (£-0.00 Mil) to Dec. 2024 (£0.00 Mil).

Shield Therapeutics's annual Other Net Income (Loss) increased from Dec. 2022 (£0.00 Mil) to Dec. 2023 (£0.00 Mil) but then declined from Dec. 2023 (£0.00 Mil) to Dec. 2024 (£0.00 Mil).

Shield Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Shield Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Other Net Income (Loss) Chart

Shield Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Shield Therapeutics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Shield Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.00 Mil.

Shield Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.